^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Zumrad (sasanlimab)

    i
    Other names: PF-06801591, PF-6801591, PF6801591, PF 6801591, RN-888 , PF06801591, PF 06801591, RN888, RN 888
    Company:
    Pfizer
    Drug class:
    PD1 inhibitor
    Related drugs:
    2d
    A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. (clinicaltrials.gov)
    P1, N=330, Recruiting, Pfizer | Trial completion date: Sep 2028 --> Jan 2029 | Trial primary completion date: Sep 2027 --> Jan 2028
    Trial completion date • Trial primary completion date • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Erbitux (cetuximab) • cisplatin • carboplatin • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • pemetrexed • oxaliplatin • leucovorin calcium • Zumrad (sasanlimab)
    28d
    SPARCC: A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma (clinicaltrials.gov)
    P2, N=25, Recruiting, Stephanie Berg | Not yet recruiting --> Recruiting
    Enrollment open
    |
    TFE3 (Transcription Factor Binding To IGHM Enhancer 3) • TFEB (Transcription Factor EB 2)
    |
    Ibrance (palbociclib) • axitinib • Zumrad (sasanlimab)
    2ms
    ?HM-87884561: Sasanlimab Treatment As Bladder-Sparing Strategy For Patients With Muscle Invasive Bladder Cancer (2024-511358-36-00)
    P1/2, N=70, Active, not recruiting, Fundacion De investigacion De Hm Hospitales | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Zumrad (sasanlimab)
    2ms
    Treatment of non-muscle-invasive bladder cancer (PubMed, Urologie)
    The therapeutic landscape of NMIBC is undergoing rapid evolution. Combination strategies and novel intravesical therapies have the potential to expand the role of BCG to reduce recurrence and progression rates and further establish bladder-preserving treatment paradigms.
    Review • Journal
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    Imfinzi (durvalumab) • Zumrad (sasanlimab)
    3ms
    A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies (clinicaltrials.gov)
    P1, N=9, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting | N=399 --> 9 | Trial completion date: Sep 2029 --> Apr 2026 | Trial primary completion date: Sep 2028 --> Mar 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Zumrad (sasanlimab)
    3ms
    A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene. (clinicaltrials.gov)
    P1, N=26, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting | N=190 --> 26
    Enrollment closed • Enrollment change • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Erbitux (cetuximab) • cisplatin • carboplatin • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • pemetrexed • oxaliplatin • leucovorin calcium • Zumrad (sasanlimab) • PF-07284892
    5ms
    Therapeutic Intensification Based on Immune Checkpoint Inhibitors in Non-Muscle Invasive Bladder Cancer: State of the Art and Future Perspectives. (PubMed, Cancers (Basel))
    Therapeutic intensification using systemic immunotherapy applies to both BCG-unresponsive NMIBC, with a new target pathway (HLA-E/NKG2A), and BCG-naïve HR NMIBC, where the combination of BCG instillations and immunotherapy represents a major breakthrough.
    Review • Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    HLA-E (Major Histocompatibility Complex, Class I, E) • KLRC1 (Killer Cell Lectin Like Receptor C1)
    |
    Keytruda (pembrolizumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Zumrad (sasanlimab) • cetrelimab (JNJ-63723283)
    5ms
    NKT2152-202: Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc) (clinicaltrials.gov)
    P2, N=18, Terminated, NiKang Therapeutics, Inc. | N=172 --> 18 | Trial completion date: Jun 2026 --> Sep 2025 | Active, not recruiting --> Terminated; This study was terminated as a result of Sponsor portfolio reprioritization.
    Enrollment change • Trial completion date • Trial termination
    |
    Ibrance (palbociclib) • Zumrad (sasanlimab) • imdatifan (NKT2152)
    6ms
    A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines. (clinicaltrials.gov)
    P1, N=9, Terminated, Pfizer | Active, not recruiting --> Terminated; Study terminated as part of strategic considerations and not based on safety concerns.
    Trial termination • First-in-human
    |
    Zumrad (sasanlimab)
    6ms
    A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer (clinicaltrials.gov)
    P1, N=294, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Zumrad (sasanlimab)
    6ms
    RAD-VACCINE: Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer (clinicaltrials.gov)
    P2, N=33, Active, not recruiting, The Methodist Hospital Research Institute | Recruiting --> Active, not recruiting | Trial completion date: Aug 2025 --> Apr 2027
    Enrollment closed • Trial completion date
    |
    Zumrad (sasanlimab)
    7ms
    A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer (clinicaltrials.gov)
    P1, N=294, Not yet recruiting, Pfizer
    New P1 trial
    |
    Zumrad (sasanlimab)